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same subjects or different ones, with the advantage of potentially limiting
biological variability in the former case. Naturally, this is much easier to
achieve in animal studies rather than human, and problems are further
compounded by the fact of greater genetic variability in man compared to
inbred mouse strains. Unfortunately, to counter such limitations increased
sample numbers are often required to obtain signiﬁcant data from array
studies involving human tissue.
Microarrays are at their most powerful when used to address very well-
deﬁned research questions, for example, what is the effect of a speciﬁc
stimulus on a given cell type?; or, indeed in many plus/minus scenarios
(including knock-downs, knock-outs etc.). Another example along these
lines is the use of so-called RIP-Chip (immunoprecipiation of speciﬁc
proteins followed by array analysis) which is very useful when looking
at interactions between a single protein and many different RNA species.
In conclusion, array studies are most useful when applied to clearly de-
ﬁned research questions, and furthermore it is crucial to perform them
with utmost care both in experimental planning and execution to obtain
meaningful data. If such an approach is adopted array studies can be
extremely powerful as they can provide genuine new insights into many
pathophysiological processes.
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Osteoarthritis (OA) is the most common joint disease, with millions of
affected individuals worldwide. The prevalence of the disease is increasing
with age and consequently the affected population is chieﬂy constituted of
frail and elderly people. Given the chronic and non-life-threatening nature
of OA, a good safety proﬁle of treatments is essential.
Intra articular (IA) therapy gives the opportunity to reduce the risks of
adverse events compared to systemic treatments such as non steroidal anti
inﬂammatory drugs and cox2-inhibitors, particularly in patients with co-
morbidities (renal failure, arterial hypertension, gastrointestinal diseases).
Furthermore the direct administration of the drug into the OA joint allows
to expose the cartilage and synovial tissues to higher concentrations of the
drug compared to those obtained via systemic route.
The main risk associated with intraarticular administration is septic arthri-
tis but this risk is very small, when proper sterile technique is used,
including sterile syringes and skin antisepsis (0.002% from the experience
of 50,000 IA injections of corticosteroids). Proper needle placement within
the intra-articular cavity deserves careful attention. Even experienced se-
nior physicians fail to place the needle within the joint cavity in 20 to
50% of cases according to the joint and the approach. For deep joints such
as the hip, or small joints such as the trapezo-metacarpial joint, imaging
guidance using ultrasonography or ﬂuoroscopy is crucial. To limit the risk of
inaccurate needle placement, aspiration of synovial ﬂuid is recommended.
Synovial ﬂuid aspiration is indispensable when there is a joint effusion and
may contribute to the treatment response either via a direct effect or by
diminishing the volume available for drug dilution.
To date, three types of IA therapies are routinely available for decreas-
ing pain and/or improving function in patients with OA: glucocorticoids,
hyaluronic acid, and joint lavage.
Steroids IA injections are recommended in patients with joint effusion and
in those with signs of inﬂammation. The short-term beneﬁt (<4 weeks)
of IA corticosteroids (CS) in the treatment of knee OA is well established
with a size effect on pain of 0.58 (95%CI 0.34-0.87), and few side effects
have been reported such as temporary disturbance of diabetes and arterial
hypertension.
The response to hyaluronic acid (HA) products appears similar (ES pain
0.60/CI 0.37-0.83) but much more durable than that of CS (up to 26
weeks). No major safety issues were reported apart from some transient
local adverse events such as pain, swelling. Recent studies also suggest
a possible structure-modifying effect of HA injections. The key question
with HA treatment is to precisely deﬁne the type of patients likely to be
responders to treatment.
Joint lavage and arthroscopic debridement are often proposed in patients
unresponsive to CS and/or HA treatments, but there is no evidence of their
eﬃcacy (ES pain 0.21/-0.12-0.54).
New perspectives of IA therapy in OA include anti-cytokine therapy, gene
therapy, delivery of growth factors, stem cells therapy and new lubricant
agents.
The main goal of IA therapy for OA in the future will be to increase the
residence time of the drug within the joint in order to improve its diffusion
within the target tissues. In all cases the treatment must be individualized
for each patient in order to adapt it to the speciﬁcs of his condition.
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OA is a multifactorial condition with genetic and environmental determi-
nants. All cases are inﬂuenced by both genetics and environment, with
the distribution and weight of causes forming a continuum between the
extremes of predominantly genetic or predominantly environmental. For
example, the risk of ‘post-traumatic OA’ after a meniscal injury of the knee
is inﬂuenced by a familial history of OA, by the presence of nodal OA of the
hand (marker of ‘generalized’ OA), by obesity, and by sex. The expression of
OA in any individual (presence or absence of inﬂammation, pain, cartilage
loss, bone formation, etc.) may further be determined by the particular mix
of genetic and environmental inﬂuences in that person.
OA where previous joint injury is identiﬁed as an important cause is
common, especially in younger persons. By 10-20 years after the rupture of
a cruciate ligament or meniscus of the knee, about half of those injured will
show radiographic signs of OA, and many will have signiﬁcant symptoms
already when aged 30 to 50. This represents an important clinical challenge
in that surgical resection or reconstruction of the torn meniscus or cruciate
ligament has not been proven to decrease the risk of OA development.
The young athlete with a knee injury leading to later OA may seem
straightforward to identify as post-traumatic OA, but the contribution
of additional risk factors as mentioned above should not be overlooked.
Moreover, the case deﬁnition is further muddled by the common presence
in middle-aged persons of incidental meniscus lesions associated with an
increased risk of knee OA development. Completing the continuum, lesions
of the menisci or cruciate ligament are frequent in OA knees, even in the
absence of a clear history of injury.
OA following joint injury offers unique opportunities for studying and
intervening in the earlier phases of human OA development. In parallel,
joint injury in the animal is a commonly used pre-clinical model for OA
development.
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Osteoarthritis (OA) is characterized by cartilage degeneration and osteo-
phyte formation in joints. Despite its high prevalence and social needs for
the disease-modifying treatment, the molecular backgrounds underlying
the OA development are not fully clariﬁed. Considering that most of risk
factors approved so far are related to accumulated mechanical stress on
joint, elucidation of signals lying downstream of the mechanical stress
will disclose the molecular backgrounds. Using mouse experimental OA
models by producing instability in the knee joints surgically, proteinases
like matrix metalloproteinase-13 (MMP)13 and aggrecanase-2 (ADAMTS-5)
have been reported to be involved in the OA development. However,
clinical trials of the proteinase inhibitors have to date been unsuccessful
in terms of eﬃcacy and side effects, turning the interest of researchers to
other signals.
Our examination using the experimental mouse model conﬁrmed that
MMP13 was induced during the OA progression in the knee joint cartilage,
but more interestingly, type X collagen (COL10A1) that is characteristic
of hypertrophic differentiation of chondrocytes was strongly expressed
prior to the MMP13 induction. Chondrocyte hypertrophy with COL10A1
expression is known to initiate the endochondral ossiﬁcation process which
is not seen in the joint cartilage under physiological conditions, but is an
essential step for skeletal growth and fracture healing. The hypertrophic
chondrocytes then degrade cartilage matrix by proteinases to cause vas-
cularization by expressing VEGF for the recruitment of osteoprogenitor
cells.
To identify signals to induce endochondral ossiﬁcation and OA develop-
